The ethics of CYP2D6 testing for patients considering tamoxifen

Anne Renee Hartman, Paul Helft

Research output: Contribution to journalComment/debatepeer-review

13 Scopus citations

Abstract

The CYP2D6 gene is responsible for the majority of tamoxifen metabolism. Recent compelling, yet limited data have determined that postmenopausal women who carry a functional polymorphism in the CYP2D6 gene have a worse clinical outcome than women who have a wild-type genotype. In this commentary we discuss the level of evidence needed to change clinical practice and whether CYP2D6 genotyping is appropriate for all women considering tamoxifen as part of their adjuvant therapy.

Original languageEnglish (US)
Article number103
JournalBreast Cancer Research
Volume9
Issue number2
DOIs
StatePublished - Apr 13 2007

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The ethics of CYP2D6 testing for patients considering tamoxifen'. Together they form a unique fingerprint.

Cite this